Treatment Algorithm for Renal Cell Carcinoma with Lung Metastases
For metastatic clear cell RCC with lung metastases, initiate first-line systemic therapy with immune checkpoint inhibitor (ICI) combinations based on IMDC risk stratification, reserving metastasectomy for highly selected patients with favorable-risk oligometastatic disease who achieve disease control on systemic therapy. 1
First-Line Systemic Therapy by IMDC Risk Group
IMDC Favorable Risk
- Primary options: Nivolumab + cabozantinib, pembrolizumab + axitinib, pembrolizumab + lenvatinib, or nivolumab + ipilimumab 1
- Alternative monotherapy: Sunitinib or pazopanib (only if ICI contraindicated) 1
IMDC Intermediate/Poor Risk
- Primary options: Nivolumab + cabozantinib, pembrolizumab + axitinib, or pembrolizumab + lenvatinib 1
- Alternative: Cabozantinib monotherapy or sunitinib (if ICI not feasible) 1
Sarcomatoid Features
Strongly prioritize ICI combinations (ipilimumab + nivolumab, axitinib + pembrolizumab, cabozantinib + nivolumab, lenvatinib + pembrolizumab, or avelumab + axitinib) over TKI monotherapy, as these demonstrate OS advantages 1
Role of Local Therapy for Lung Metastases
Observation Strategy for Oligometastatic Disease
For patients with initial oligometastatic lung disease, observation for up to 15 months is appropriate before initiating systemic therapy, provided careful reassessment rules out rapid progression 1. This approach allows identification of patients with indolent biology who may benefit from delayed systemic treatment.
Pulmonary Metastasectomy Indications
Consider metastasectomy only when:
- Complete resection is technically achievable
- Favorable or intermediate IMDC risk classification
- No extrapulmonary metastases present
- Disease control achieved on systemic therapy
- Solitary or limited number of metastases
- Long disease-free interval from primary nephrectomy 2, 3
Critical caveat: The 2025 EAU guidelines explicitly recommend against metastasectomy within 1 year of initial diagnosis followed by adjuvant pembrolizumab, as this approach has not proven superior to observation followed by dual ICI-based therapy upon progression 1. This represents a significant shift from historical practice patterns.
Stereotactic Radiosurgery/Radiotherapy
For patients who are not surgical candidates or have unresectable disease:
- Robotic radiosurgery achieves 96.7% local control at 2 years for lung metastases with minimal toxicity (grade ≤2 only) 4
- Conventional radiotherapy provides 84.5% 5-year metastasis control for lung lesions 5
- Particularly valuable for preventing life-threatening complications (airway compromise, vascular invasion) with 88.9% 1-year control 5
Second-Line and Beyond
After progression on first-line ICI + TKI or dual ICI:
- Sequencing with atezolizumab + cabozantinib showed no benefit over single-agent TKI in the CONTACT 03 trial 1
- Consider any first-line recommended agent not previously used
- Single-agent TKI (cabozantinib, sunitinib) remains reasonable
- Best supportive care is appropriate for selected patients 6
Non-Clear Cell Histologies
Papillary RCC
- First-line: Cabozantinib monotherapy (preferred based on PFS advantage over sunitinib) 6
- Alternatives: Pembrolizumab monotherapy, sunitinib, or combinations (lenvatinib + pembrolizumab, cabozantinib + nivolumab) 6
Other Rare Histologies
- Collecting duct/SMARCB1-deficient: Platinum-based chemotherapy 6
- FH-deficient/HLRCC: Bevacizumab + erlotinib 6
- Chromophobe: Consider mTOR inhibitors 6
Key Clinical Pitfalls
Do not perform early metastasectomy with adjuvant pembrolizumab within 1 year of diagnosis—this strategy is inferior to observation with systemic therapy at progression 1
Biopsy suspicious lung lesions when feasible, as 22% of patients with metastatic RCC may develop primary NSCLC, particularly in smokers 7. Look for radiographic features suggesting primary lung cancer (spiculation, cavitation, discordant treatment response).
Avoid surgery in poor-risk patients with rapidly progressive disease—systemic therapy should be prioritized 6
Monitor for rare but life-threatening endobronchial metastases that may cause acute airway obstruction requiring urgent bronchoscopic intervention 8
Mediastinal metastases have inferior local control (43.4% at 3 years) compared to lung parenchymal lesions (84.5% at 3 years) with radiotherapy 5